Concurrent use is not uncommon and normally appears to beuneventful. However,three patients became drowsy, forgetfuland appeared uncoordinated and drunk while taking amitriptyline and chlordiazepoxide. A combined preparation of amitriptyline and chlordiazepoxide (Limbitrol) is available but its advantages have been questioned: adverse effects have been seenin four patients. Diazepam may increase risks of carrying outcomplex tasks (e.g. driving) if added to amitriptyline,as may other combinations of benzodiazepines and tricyclics.
Chlordiazepoxide. Clinical studies in large numbers of patients have shown that incidence of adverse reactions while taking amitriptyline and chlordiazepoxide was no greater than might have been expected with either of drugs used alone,(See reference number 1-3) but a few adverse reports have been documented. A depressed patient taking amitriptyline 150mg and chlordiazepoxide 40mg daily became confused,forgetful and uncoordinated. He acted as though he was drunk (See reference number 4). Two other patients taking amitriptyline and chlordiazepoxide experienced drowsiness, memory impairment, slurring of speech and an inability to concentrate. Both were unable to work and one described himself as feeling drunk (See reference number 5). Four patients taking Limbitrol are reported to have experienced some manifestations of toxicity (delusions,confusion, agitation, disorientation, dry mouth, blurred vi-sion) (See reference number 6). Some of these effects seem to arise from increased CNS depression (possibly additive) and/or an increase in antimuscarinic adverse effects of tricyclic.
Diazepam. A study demonstrated an increase in amitriptyline levels when diazepam was given,(See reference number 7) and two others found that addition of diazepam to amitriptyline 50 to 75mg further reduced attention and performance of a number of psychomotor tests (See reference number 8,9). In contrast,two studies suggested that diazepam did not affect amitriptyline levels (See reference number 3,10).
Studies on effects of nitrazepam and oxazepam on steady-state plasma levels of amitriptyline;(See reference number 3)did not find any interactions
An in vitro study in human liver microsomes found that alprazolam does not affect metabolism (hydroxylation) of desipramine (See reference number 12)
tients taking imipramine, and does not reduce effects of antidepressant.16,17
Zaleplon. A single 75mg dose of imipramine had no effect on pharmacokinetics of zaleplon 20 mg, and psychomotor tests showed only short term additive effects lasting 1 to 2 hrs (See reference number 18).
Zolpidem. A single-dose study using zolpidem 20mg and imipramine 75mg found no effect on pharmacokinetics of either drug. However, imipramine increased sedative effects of zolpidem, and anterograde amnesia was seen (See reference number 19).
Lorazepam may be useful for anxiety or insomnia in elderly depressed patients without impairing response to treatment with nortriptyline (See reference number 20)
Studies on effects of alprazolam, chlordiazepoxide, diazepam, nitrazepam and oxazepam on steady-state plasma levels of nortriptyline(See reference number 3,12,21)found no interactions.
In a study in 10 healthy subjects, when zopiclone and trimipramine were given concurrently for a week, bioavailability of zopiclone was reduced by almost 14 % and bioavailability of trimipramine by almost 27%, but neither of these changes were statistically significant (See reference number 22).
There seems to be no reason for avoiding concurrent use of benzodiazepines and tricyclics although advantages and disadvantages remain subject of debate. Other combinations of tricyclic antidepressants and benzodiazepines would not be expected to behave differently from those described here. Some patients will possibly experience increased drowsiness and inattention with more sedative antidepressants such as amitriptyline, particularly during first few days, and this may be exaggerated by benzodiazepines such as diazepam. Driving risks may therefore be increased.
Haider I. A comparative trial of Ro4–6270 and amitriptyline in depressive illness. Br J Psychiatry (1967) 113,993–8.
General Practitioner Clinical Trials. Chlordiazepoxide with amitriptyline in neurotic depression. Practitioner (1969) 202,437–40.
Silverman G,Braithwaite RA. Benzodiazepines and tricyclic antidepressant plasma levels.BMJ (1973) 3, 18–20.
Kane FJ,Taylor TW. A toxic reaction to combined Elavil-Librium therapy. Am J Psychiatry (1963) 119, 1179–80.
Abdou FA. Elavil-Librium combination. Am J Psychiatry (1964) 120,1204.
Beresford TP,Feinsilver DL, Hall RCW. Adverse reactions to a benzodiazepine-tricyclicantidepressant compound. J Clin Psychopharmacol (1981) 1, 392–4.
Dugal R,Caille G, Albert J-M, Cooper SF. Apparent pharmacokinetic interaction of diazepam and amitriptyline in psychiatric patients: a pilot study. Curr Ther Res (1975) 18, 679–
Patat A,Klein MJ, Hucher M, Granier J. Acute effects of amitriptyline on human performance and interactions with diazepam. Eur J Clin Pharmacol (1988) 35, 585–92.
Moskowitz H,Burns M. The effects on performance of two antidepressants, alone and incombination with diazepam. Prog Neuropsychopharmacol Biol Psychiatry (1988) 12, 783–
Otani K,Nordin C, Bertilsson L. No interaction of diazepam on amitriptyline disposition indepressed patients. Ther Drug Monit (1987) 9, 120–2.
Carson SW,Wright CE, Millikin SP, Lyon J, Chambers JH. Pharmacokinetic evaluation ofthe combined administration of alprazolam and clomipramine. Clin Pharmacol Ther (1992) 51, 154.
Bertilsson L,Åberg-Wistedt A, Lidén A, Otani K, Spina E. Alprazolam does not inhibit themetabolism of nortriptyline in depressed patients or inhibit the metabolism of desipramine inhuman liver microsomes. Ther Drug Monit (1988) 10, 231–3.
Deicken RF. Clonazepam-induced reduction in serum desipramine concentration. J Clin Psychopharmacol (1988) 8,71–3.
Elko CJ,Burgess JL, Robertson WO. Zolpidem-associated hallucinations and serotonin re-uptake inhibition: a possible interaction. Clin Toxicol (1998) 36, 195–203.
Grasela TH,Antal EJ, Ereshefsky L, Wells BG, Evans RL, Smith RB. An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction.Clin Pharmacol Ther (1987) 42, 433–41.
Cohn JB. Triazolam treatment of insomnia in depressed patients taking tricyclics. J Clin Psychiatry (1983) 44,401–6.
Dominguez RA,Jacobson AF, Goldstein BJ, Steinbook RM. Comparison of triazolam andplacebo in the treatment of insomnia in depressed patients. Curr Ther Res (1984) 36, 856–65.
Darwish M. Overview of drug interaction studies with zaleplon. Poster presented at 13(See reference number th) Annual Meeting of Associated Professional Sleep Studies (APSS),Orlando, Florida, June 23(See reference number rd), 1999.
Sauvanet JP,Langer SZ, Morselli PL, eds. Imidazopyridines in Sleep Disorders. New York:Raven Press; 1988 p. 165–73.
Buysse DJ,Reynolds CF, Houck PR, Perel JM, Frank E, Begley AE, Mazumdar S, KupferDJ. Does lorazepam impair the antidepressant response to nortriptyline and psychotherapy?J Clin Psychiatry (1997) 58, 426–432.
Gram LF,Overo KF and Kirk L. Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man. Am J Psychiatry (1974) 131, 863.
Caille G,Du Souich P, Spenard J, Lacasse Y, Vezina M. Pharmacokinetic and clinical parameters of zopiclone and trimipramine when administered simultaneously to volunteers. Biopharm Drug Dispos (1984) 5, 117–25.